These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31622241)

  • 1. Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents.
    Bornhorst J; Wegwerth P; Day P; Bryant S; Rokke D; Tervola R; Eckdahl S; Jannetto PJ
    Clin Chem Lab Med; 2020 Feb; 58(3):e87-e90. PubMed ID: 31622241
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study.
    Alwasiyah D; Murphy C; Jannetto P; Hogg M; Beuhler MC
    J Med Toxicol; 2019 Apr; 15(2):121-127. PubMed ID: 30543028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic gadolinium-based contrast agents: the future?
    Thomsen HS
    Acta Radiol; 2017 Nov; 58(11):1285-1287. PubMed ID: 28691527
    [No Abstract]   [Full Text] [Related]  

  • 4. Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.
    Blumfield E; Swenson DW; Iyer RS; Stanescu AL
    Pediatr Radiol; 2019 Apr; 49(4):448-457. PubMed ID: 30923876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Stability" of gadolinium chelates.
    Tweedle MF
    Br J Radiol; 2007 Jul; 80(955):583-4; author reply 584-5. PubMed ID: 17704319
    [No Abstract]   [Full Text] [Related]  

  • 6. The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure.
    DeAguero J; Howard T; Kusewitt D; Brearley A; Ali AM; Degnan JH; Jett S; Watt J; Escobar GP; Dokladny K; Wagner B
    Sci Rep; 2023 Feb; 13(1):2025. PubMed ID: 36739294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks.
    Unruh C; Van Bavel N; Anikovskiy M; Prenner EJ
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33297578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P
    J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
    [No Abstract]   [Full Text] [Related]  

  • 10. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A; Kirchin MA; Pirovano G
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract]   [Full Text] [Related]  

  • 12. [Are rare earths used in offshore windpower installations toxic?].
    Goullé JP; Saussereau E; Lacroix C; Guerbet M; Cabanis EA
    Bull Acad Natl Med; 2012 Oct; 196(7):1457-61. PubMed ID: 23815027
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical value of negative skin tests to gadolinium contrast agents.
    Chiriac AM; Audurier Y; Bousquet PJ; Demoly P
    Allergy; 2011 Nov; 66(11):1504-6. PubMed ID: 21854399
    [No Abstract]   [Full Text] [Related]  

  • 14. Distribution and chemical forms of gadolinium in the brain: a review.
    Kanda T; Nakai Y; Hagiwara A; Oba H; Toyoda K; Furui S
    Br J Radiol; 2017 Nov; 90(1079):20170115. PubMed ID: 28749164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: a chemical perspective.
    Rofsky NM; Sherry AD; Lenkinski RE
    Radiology; 2008 Jun; 247(3):608-12. PubMed ID: 18487530
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.
    Garcia J; Liu SZ; Louie AY
    Philos Trans A Math Phys Eng Sci; 2017 Nov; 375(2107):. PubMed ID: 29038383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of magnetic resonance imaging agents: small molecule and nanoparticle.
    Chang Y; Lee GH; Kim TJ; Chae KS
    Curr Top Med Chem; 2013; 13(4):434-45. PubMed ID: 23432006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of magnetic resonance contrast media.
    Runge VM
    Top Magn Reson Imaging; 2001 Aug; 12(4):309-14. PubMed ID: 11687717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.